9 / 22
conferenceseries LLC Ltd
Notes:
Page 40
Clinical Pharmacology & Biopharmaceutics | ISSN : 2167-065X
Volume 7
September 18-19, 2018 | Amsterdam, Netherlands
6
th
European Biopharma Congress
Euro Biopharma 2018
Clin Pharmacol Biopharm 2018, Volume:7
DOI: 10.4172/2167-065X-C1-029
Development of a novel drug delivery system comprising biopharmaceuticals for dermal and nail delivery
Flavia Laffleur
University of Innsbruck, Austria
P
redominantly, the majority of fungal infections (dermal and nail) are caused by dermatophytes, such as
Trichophyton rubrum
known
as one of the most prominent. Among fungal infections, nail infections or onychomycosis exhibit the most difficulties and limitations
in their treatment. Onychomycosis affects around 5-10% of the population in the world. Onychomycosis is a common infection of the nail
caused by dermatophyte affecting mostly toenails in adults being associated with limited treatment options. In this study novel dosage forms
were prepared and evaluated for their suitability in treatment of onychomycosis. Films were prepared comprising polymeric excipients such
as chitosan, (hydroxypropyl) methyl cellulose, hydroxyethyl-cellulose, carboxymethylcellulose according to solvent evaporation method.
Developed formulations were evaluated in terms of physical appearance, stability and adhesiveness. Furthermore skin and nail irritation
studies were conducted. Five potential formulations (F1-F5) were designed while F1 and F4 exhibited the most promising results in terms
of stability with 26 min and 40-67 min, respectively, and suitability in nail application. F1 as the most favorable dosage form revealed with
2.9438 kg/m/s in terms of adhesive force the most adhesive properties in contrast to the other preparations. All formulations were found
to be non-skin irritating and safe to use. Taken together, these findings suggest novel designed films containing polymeric excipients as a
fruitful platform for the treatment in onychomycosis.
Flavia.Laffleur@uibk.ac.at